Skip to main content
Wouter Plattel
dr.

As a hematologist I am always looking for new development that might improve patient care. My main research focus is on patients with Hodgkin lymphoma and multiple myeloma. I am involved in both translational and clinical studies. In cooperation with the Pathology, I am active in the field of biomarkers, such as TARC in Hodgkin lymphoma. For the design, development and execution of clinical trials, I am an active member of both international (EORTC) and national (HOVON) organizations. For example, I am the national PI of the EORTC COBRA trial in Hodgkin lymphoma. Moreover, I am co-PI of the translational research in two international trials. In addition, I am part of the Dutch guideline writing committee for Hodgkin lymphoma. In myeloma, I am investigating innovative treatment options to improve outcome.

Prognostic value of comorbidity for auto-SCT eligibility and outcome in relapsed or refractory aggressive non-Hodgkin’s lymphoma
Published in: Bone marrow transplantation
Access to document 10.1038/bmt.2010.188
Salvage reinduction therapy followed by high-dose chemotherapy (HDCT) and auto-SCT is the treatment of choice for fit patients with refractory or relapsed aggressive non-Hodgkin’s lymphoma (NHL). We assessed the prognostic value of comorbidity at the time of relapse to predict receipt of auto-SCT and outcome. We analyzed 156 consecutive NHL patients, referred to our center between 1999 and 2007 for salvage reinduction therapy, followed by HDCT and auto-SCT. Comorbidity according to the hematopoietic SCT comorbidity index was scored at relapse and directly before HDCT and auto-SCT. Primary end...
W J Plattel, H C Kluin-Nelemans, G H de Bock, G W van Imhoff
EXPRESSION OF THE C-MET ONCOGENE CORRELATES WITH FAVORABLE PROGRESSION FREE SURVIVAL IN CLASSICAL HODGKIN LYMPHOMA
C. Xu, A. van den Berg, W. Plattel, N. Ruether, X. Huang, M. Wang, D. de Jong, H. Vos, G. van Imhoff, A. Viardot, P. Moeller, S. Poppema, A. Diepstra, L. Visser
PROSPECTIVE ANALYSIS OF PLASMA LEVELS OF THYMUS AND ACTIVATION REGULATED CHEMOKINE (TARC) IN PRIMARY AND RELAPSED CLASSICAL HODGKIN LYMPHOMA PATIENTS
W. Plattel, A. van den Berg, A. M. Van der Graaf, S. Poppema, L. Visser, A. Diepstra, G. W. Van Imhoff
EXPRESSION OF THE C-MET ONCOGENE CORRELATES WITH FAVORABLE PROGRESSION FREE SURVIVAL IN CLASSICAL HODGKIN LYMPHOMA
C. Xu, A. van den Berg, W. Plattel, N. Ruether, X. Huang, M. Wang, D. de Jong, H. Vos, G. van Imhoff, A. Viardot, P. Moeller, S. Poppema, A. Diepstra, L. Visser
PROSPECTIVE ANALYSIS OF PLASMA LEVELS OF THYMUS AND ACTIVATION REGULATED CHEMOKINE (TARC) IN PRIMARY AND RELAPSED CLASSICAL HODGKIN LYMPHOMA PATIENTS
W. Plattel, A. van den Berg, A. M. Van der Graaf, S. Poppema, L. Visser, A. Diepstra, G. W. Van Imhoff